Aveo, Astellas end pact to develop cancer drug Tivozanib

[Reuters] – Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo’s lead experimental drug and said they would discontinue a mid-stage study testing its use in colon cancer. Aveo said in January it would end a mid-stage t more

View todays social media effects on AVEO

View the latest stocks trending across Twitter. Click to view dashboard

See who AVEO is hiring next, click here to view